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Abstract
The basal-like subtype of breast cancer is associated with invasiveness, high rates of postsurgical recurrence, and
poor prognosis. Aside from inactivation of the BRCA1 tumor-suppressor gene, little is known concerning the
mechanisms that cause basal breast cancer or the mechanisms responsible for its invasiveness. Here, we show
that the heterogeneous mouse mammary tumor virus–cyclin D1–Cdk2 (MMTV-D1K2) transgenic mouse mammary
tumors contain regions of spindle-shaped cells expressing both luminal and myoepithelial markers. Cell lines cul-
tured from these tumors exhibit the same luminal/myoepithelial mixed-lineage phenotype that is associated with
human basal-like breast cancer and express a number of myoepithelial markers including cytokeratin 14, P-cadherin,
α smooth muscle actin, and nestin. The MMTV-D1K2 tumor–derived cell lines form highly invasive tumors when
injected into mouse mammary glands. Invasion is associated with E-cadherin localization to the cytoplasm or loss
of E-cadherin expression. Cytoplasmic E-cadherin correlates with lack of colony formation in vitro and β-catenin and
p120ctn localization to the cytoplasm. The data suggest that the invasiveness of these cell lines results from a com-
bination of factors including mislocalization of E-cadherin, β-catenin, and p120ctn to the cytoplasm. Nestin expression
and E-cadherin mislocalization were also observed in human basal-like breast cancer cell lines, suggesting that these
results are relevant to human tumors. Together, these results suggest that abnormal Cdk2 activation may contribute
to the formation of basal-like breast cancers.
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Introduction
Microarray analyses have recently allowed breast tumors to be cate-
gorized as luminal, basal-like, normal-like, or Her2-positive based on
distinct gene expression profiles, morphologic characteristics, prog-
nostic outcomes, and responsiveness to currently available therapeu-
tic approaches [1,2]. The basal-like subtype represents approximately
20% of human breast cancers overall but 39% of breast tumors in
premenopausal African American women [3]. These tumors are as-
sociated with a high rate of recurrence and poor outcome [2]. The
basal-like subtype of cancers is also termed triple negative because
these tumors typically lack estrogen receptor (ER), progesterone re-
ceptor, and Her2 overexpression but generally express a subset of
myoepithelial markers, including cytokeratin 14 (CK14), CK5, α
smooth muscle actin (αSMA), nestin, or p63 (reviewed in [4–6]).
Basal-like tumors lack responsiveness to tamoxifen and aromatase
inhibitors that target ER-positive luminal tumors and herceptin that
targets Her2-positive tumors.
Abbreviations: Cdk, cyclin-dependent kinase; CK, cytokeratin; CK14, cytokeratin 14;
DAPI, 4′,6-diamidino-2-phenylindole; D1K2, cyclin D1–Cdk2 fusion protein;
EGFR, epidermal growth factor receptor; EMT, epithelial-to-mesenchymal transition;
H&E, hematoxylin and eosin; MMTV, mouse mammary tumor virus; αSMA or
SMA, alpha smooth muscle actin; TGFβ, transforming growth factor beta
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The mouse basal-like breast cancer models described to date in-
volve genetic deletion of the BRCA1 and p53 tumor-suppressor genes
[7,8]. Tumors initiated by BRCA1 inactivation in mice express the
progesterone receptor [9] and overexpress Her2 [10] and thus do
not fit the triple negative clinical definition of basal breast cancer.
Therefore, it is likely that additional genetic lesions contribute to
the formation of sporadic human basal-like breast cancers. Micro-
array studies have suggested several candidate “drivers” of basal breast
cancer including epidermal growth factor receptor (EGFR), c-Kit,
c-Met, and cyclin E. However, none of these genes have yet been
demonstrated to specifically induce basal-like breast cancer when over-
expressed. Interestingly, human basal-like breast tumors frequently
exhibit p16 overexpression, low levels of Rb and cyclin D1 expression,
and high levels of cyclin E expression [11]. Based on these observa-
tions, it was proposed that Rb inactivation is mechanistically linked
to the basal-like subtype [11]. Together, these results suggest that
basal-like tumors may have low levels of Cdk4/Cdk6 activity but per-
haps high levels of Cdk2 activity.
We previously described a novel mouse transgenic model of breast
cancer in which expression of a cyclin D1–Cdk2 (D1K2) fusion protein
[12] under the control of the mouse mammary tumor virus (MMTV)
promoter/enhancer induces mammary tumorigenesis (MMTV-D1K2
animals) [13]. Mammary tumors from these animals exhibit Rb hyper-
phosphorylation, high levels of Cdk2 activity, and up-regulation of
E2F-dependent transcription [13]. Thus, MMTV-D1K2 tumors exhibit
functional inactivation of Rb tumor-suppressor activity.
MMTV-D1K2 tumors are heterogeneous and induce a desmoplas-
tic reaction associated with transforming growth factor beta (TGFβ)
secretion by the cancer cells. As mentioned previously [13], some of
the cancer cell lines derived from the MMTV-D1K2 tumors exhibit
the morphologic features of myoepithelial cells. Here, we report a
more extensive characterization of MMTV-D1K2 cell lines and dem-
onstrate that these cells express protein markers associated with the
basal/myoepithelial lineage.
E-cadherin is a potent invasion suppressor expressed in nontrans-
formed mammary epithelial cells [14]. The MMTV-D1K2 cell lines
exhibit decreased or mislocalized E-cadherin expression in culture.
Introduction of cell lines derived from MMTV-D1K2 tumors into
the mammary glands of wild type syngeneic mice results in the for-
mation of invasive tumors composed of spindle-shaped cells that ex-
hibit E-cadherin mislocalization to the cytoplasm and the expression
of basal/myoepithelial markers. Morphologic and immunohisto-
chemical analyses of the primary tumors demonstrate a biphasic mor-
phology characteristic of adenomyoepithelial-type carcinoma with
populations of spindle-shaped cells. These spindle-shaped cells ex-
hibit E-cadherin down-regulation and localization to the cytoplasm
and expression of the myoepithelial marker αSMA. These studies in-
dicate the presence of a subpopulation of invasive basal-like breast
cancer cells in the primary MMTV-D1K2 tumors.
In vitro analysis of multiple clonal cell lines derived from MMTV-
D1K2 tumors demonstrate the expression of various subsets of myo-
epithelial and luminal epithelial markers, a finding consistent with
the “mixed-lineage” properties of human basal breast cancers [15–
17]. In all of the cell lines isolated, E-cadherin expression is either
low and/or mislocalized to the cytoplasm. E-cadherin mislocalization
is associated with the inability of the cells to form colonies with nor-
mal cell-cell contacts in culture and correlates with the lack of β-
catenin and p120ctn staining at cell-cell junctions. In some cell lines,
decreased E-cadherin expression is associated with an increase in
N- or P-cadherin expression. This “cadherin switch” from E- to
N-cadherin expression is associated with increased invasiveness and
part of the epithelial-to-mesenchymal transition (EMT) that occurs
during the progression of some tumor types [18]. Epithelial-to-
mesenchymal transition has been shown to occur in the basal-like
category of breast cancers [19].
Materials and Methods
Isolation of Tumor Cell Lines
MMTV-D1K2 cancer cell lines were isolated essentially as de-
scribed [13]. When differential trypsinization was performed, the
cells remaining adherent to the flasks and the detached cells were re-
tained. This is critical because several of the basal breast cancer cell
lines adhere very loosely to tissue culture flasks or flasks coated with
rat tail collagen. The loosely adherent myoepithelial-like cancer cells
were separated from myofibroblasts by taking advantage of their dif-
ferential rates of adhesion. The cancer cells were cloned by limiting
dilution. All cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% heat-inactivated fetal
bovine serum (35-011-CV; Mediatech, Inc., Manassas, VA).
Preparation and Analysis of Tumor and Cell Extracts
by Immunoblot
Cell extracts were prepared as described [13], and immunoblot analy-
sis was performed using antibodies from Santa Cruz Biotechnology,
Inc. [Santa Cruz, CA; N-cadherin (sc-7939), P-cadherin (sc-7893),
vimentin (sc-32322), nestin (sc-23927), β-catenin (sc-7199), zyxin
(sc-6437), p130 (sc-317), Cdk2 (sc-163), actin (1616), and p53
(sc-100)] and Sigma-Aldrich [St. Louis, MO; Flag, M2 (F-3165)
and αSMA (A-2547)]. Antibodies specific for EGFR (#2232) were
obtained from Cell Signaling Technology, Inc. (Danvers, MA). p53
antibodies were also obtained from Oncogene Science (Cambridge,
MA). Antibodies specific for CK14 (MS-115) and Her2/neu (MS-
730) were obtained from LabVision/Neomarkers, Inc. (Fremont,
CA). p120 catenin (610133) antibody was obtained from BD Trans-
duction Laboratories (San Diego, CA).
Tumor samples contain large amounts of immunoglobulin, which
interferes with subsequent immunoblot and immunoprecipitation
assays. Tumor-associated immunoglobulin was removed by preclearing
aliquots of tumor lysate containing 1 mg of protein with 100 μl/tube
packed Protein G-Sepharose (10-1242; Invitrogen, Carlsbad, CA).
The supernatants were retained for subsequent analyses.
Immunofluorescence Microscopy
Cells were plated onto glass coverslips in six-well plates. After a
24-hour incubation, cells were fixed with 1% paraformaldehyde
in phosphate-buffered saline (PBS) for 20 minutes, followed by a
10-minute incubation with quench solution (50 mM ammonium chlo-
ride + 0.5% Triton X-100 in PBS). The cells were then blocked for
1 hour with an antibody buffer (10% goat serum + 0.5% Triton X-100
in PBS). Primary staining was performed using the following anti-
bodies at a 1:100 dilution in antibody buffer for 2 hours: CK14
(MS-115; Neomarkers, Inc.); E-cadherin (610181) and p120 catenin
(610133) from BD Biosciences Pharmingen; E-cadherin (24E10)
from Cell Signaling Technology, Inc.; and zyxin (sc-6437), β-catenin
(sc-7199), and N-cadherin (sc-7939) from Santa Cruz Biotechnol-
ogy, Inc. After four washes with PBS, cells were incubated with sec-
ondary antibody for 1 hour using either goat anti–Rabbit Fluor 488
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(A11008; Invitrogen Molecular Probes), goat anti–Mouse Fluor 488
(A11001; Invitrogen Molecular Probes), rabbit anti–Goat Fluor 488
(A11078; Invitrogen Molecular Probes), or goat anti–Mouse Cy3
(81-6515; Zymed, Carlsbad, CA), at either a 1:200 dilution in anti-
body buffer for single staining or a 1:300 dilution for double stain-
ing. After four washes with PBS, coverslips were mounted onto
slides with Vectashield + 4′,6-diamidino-2-phenylindole (DAPI;
H-1200; Vector Laboratories, Burlingame, CA). Actin was visual-
ized using Texas Red-X Phalloidin (T7471; Invitrogen Molecular
Probes) added during the secondary staining step at a dilution of five
units per slide. Images were captured using an upright microscope
(Axioplan2; Zeiss, Thornwood, NY) and visualized using Openlab
5.3.0 Improvision software.
Orthotopic Tumor Growth Studies
Cells in log growth phase were collected by trypsin digestion, sus-
pended in 10% FBS-DMEM, and washed three times with Hank’s
balanced salt solution (HBSS) (21-020-CV; Mediatech, Inc.). The
cells were counted and diluted to a concentration of 107 cells/ml
in HBSS. The cell suspension (100 μl) was injected into the #4
mammary glands of adult wild type female FvB mice just beneath
the surface of the nipple. Three mice were injected with each poly-
clonal cell line, and tumor formation occurred from 2 to 6 weeks
in all of the injected animals. Tumors were excised at a small size
(2-6 mm in diameter) so that tumor invasion into the surrounding
stroma could be observed.
Immunohistochemical Analysis of Tumor Tissue Sections
Two-micrometer serial sections of paraformaldehyde-fixed, paraffin-
embedded tumor tissue were dewaxed in Tissue-Clear (Sakura Finetek
Europe, Zouterwoude, The Netherlands) and hydrated through a
series of diluted ethanol followed by antigen retrieval in 10 mM Tris,
pH 9.0, 0.5 mM EGTA solution using microwave oven treatment
(15 minutes). Immunostaining was performed with a commercially
available kit (Animal Research Kit, ARK; DakoCytomation, Glostrup,
Denmark) in accordance with the manufacturer’s instructions. Addi-
tional blocking of endogenous biotin was performed with the DAKO
Biotin Blocking System (DakoCytomation) in accordance with the
manufacturer’s instructions. The following antibodies were used:
monoclonal mouse anti–human SMA, clone 1A4, dilution 1:200 and
monoclonal mouse anti–human E-cadherin, clone NCH-38, dilution
1:25 (both from DakoCytomation); and monoclonal mouse anti–
human keratin 14 Ab-1, clone LL002, dilution 1:400 (LabVision/
NeoMarkers Inc.). Images were captured using a microscope (BX51;
Olympus, Center Valley, PA) equipped with a Color View camera using
AnalySIS getIT version 5.0 (Soft Imaging System, Munster, Germany).
The tumor analyzed by immunohistochemistry in Figure 5A is
from a 58-year-old white woman diagnosed with invasive ductal car-
cinoma, grade III. Morphologically, the tumor is described as a “ring
carcinoma” because of its necrotic center.
Results
MMTV-D1K2 Hypercellular Lesions Exhibit an
Invasive Phenotype
We have previously described tumors arising in transgenic mice
in which a cyclin D1–Cdk2 fusion protein [12] is driven by the
MMTV promoter/enhancer, termed MMTV-D1K2 animals [13].
Tumors arising in these animals are heterogeneous and contain ductal
structures surrounded by spindle-shaped cells. The identity of these
spindle-shaped cells is unclear. However, these cells are of interest
because they seem to invade into the surrounding mammary fat pad
(Figure 1A). This is in contrast to MMTV-neu tumors or tumors de-
rived from MMTV-neu tumor cells that show well-demarcated bound-
aries (Figure 1B). We isolated cell lines from different MMTV-D1K2
tumors to more fully characterize the cell types composing them. Sev-
eral of the cell lines, including D1K2-T2 and D1K2-T4, display fea-
tures in culture similar to that of primary myoepithelial cells [20–23]
including an elongated morphology, multiple cellular extensions or
processes, and a relative lack of cell-cell adhesion (Figure 1C ). The
BT549 human basal-like breast cancer cell line [24] exhibits a similar
morphology. In contrast, nontransformed mouse mammary epithelial
NMuMG cells have a cuboidal shape and form distinct colonies that
exhibit a “cobblestone” morphology.
MMTV-D1K2 Tumor Cells Display Characteristics
Consistent with Basal-like Breast Cancer
Because the MMTV-D1K2 tumor–derived cell lines exhibit a
myoepithelial morphology, we examined whether they expressed
myoepithelial markers. Immunoblot analysis indicates that the cell
lines derived from MMTV-D1K2 tumors express varying amounts
of several basal/myoepithelial markers including P-cadherin, EGFR,
CK14, αSMA, and nestin (Figure 2A). In contrast, the neuT cell line
derived from an MMTV-neu tumor [13] expresses low or undetect-
able levels of these basal markers. Several of the D1K2 cell lines also
express the luminal epithelial marker E-cadherin. Because the poly-
clonal D1K2 cell lines exhibit a variety of cell morphologies, clonal
cell lines were isolated. Specifically, the D1K2-T2,CL1 and D1K2-
T2,CL6 clonal lines exhibit different morphologies in culture and
different expression profiles in immunoblot analyses. This observa-
tion indicates that the cancer cell lines isolated are heterogeneous
and is consistent with the heterogeneous nature of the primary tu-
mors [13]. The D1K2-T4 cell line does not exhibit detectable trans-
gene expression (Figure 2A), although the DNA from this cell line
tests positive for the presence of the transgene by polymerase chain
reaction analysis (not shown). Thus, expression of the cyclin D1–
Cdk2 fusion protein may not be required for maintenance of the
basal-like/myoepithelial phenotype. The D1K2 tumor cell lines express
high levels of the intermediate filament protein nestin (Figure 2A),
which was shown to be a basal breast cancer/myoepithelial marker
[4]. Quantitative proteomic analyses of protein extracts from the inva-
sive D1K2 tumor cell lines and the BT549 cell line indicate that these
cells express higher levels of the structural protein zyxin than the neuT
and mouse mammary gland NMuMG cell lines (proteomic analyses
will be described in detail elsewhere). This was verified by immunoblot
(Figure 2A).
The cell lines isolated from the MMTV-D1K2 tumors might rep-
resent a small fraction of the cells present in the primary tumors and
therefore may not be typical of the overall tumor composition. Im-
munoblot analyses of the primary tumors (Figure 2B) demonstrated
that the tumor from which the D1K2-T1 cell line was derived ex-
pressed relatively high levels of the D1K2 fusion protein as measured
by staining with Flag antibody (Flag (D1K2)). The tumor of origin
of the D1K2-T1 cells also displayed low Her2 expression, high levels
of E-cadherin expression, and low levels of αSMA staining. The
tumor from which the D1K2-T4 cell line was derived did not express
the cyclin D1–Cdk2 fusion protein and expressed low levels of
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E-cadherin, low levels of Her2, and high levels of αSMA. MMTV-
neu tumors exhibit high Her2 expression that correlates with high
E-cadherin expression. In contrast, αSMA expression is inversely re-
lated to Her2/neu transgene expression and E-cadherin expression.
Collectively, these results suggest that the cell lines isolated for analy-
sis have protein expression patterns similar to the primary tumors.
The lack of expression of the cyclin D1–Cdk2 transgene product
in the D1K2-T4 cell line and in the primary tumor from which it
was derived was unexpected because these cells resemble the other
MMTV-D1K2 cell lines in their morphology and expression pattern
of luminal and basal markers. Immunoblot analyses were performed
to examine the possibility that other molecular changes occurred that
might substitute for D1K2 expression. The results showed that the
D1K2-T4 cell line exhibited several features that could render D1K2
expression dispensable including cyclin A overexpression, (presumably
mutant) p53 overexpression, and low levels of Rb and p21 expression
(Figure 2C).
MMTV-D1K2 Tumor Lines Display Mixed Luminal/
Myoepithelial Character
In the normal mammary gland, E-cadherin is expressed in lu-
minal epithelial cells, whereas αSMA and CK14 are expressed in
myoepithelial cells. The observation that luminal proteins such as
E-cadherin and myoepithelial markers such as αSMA and CK14
are expressed in the same polyclonal cell population could be ex-
plained by the presence of cell subpopulations that each express dif-
ferent subsets of markers. Clonal cell lines were derived from the
MMTV-D1K2 tumor cell lines to determine whether these luminal
and myoepithelial markers are expressed in the same cells. Immuno-
blot analysis indicates that in multiple cases the clonal cell lines
express luminal markers such as E-cadherin and CK19 and also ex-
press basal/myoepithelial markers such as P-cadherin, EGFR, CK14,
αSMA, and nestin (Figure 3A). Interestingly, two of the four D1K2-
T4 subclones exhibit p53 overexpression.
Immunofluorescence microscopy experiments demonstrated that
the D1K2-T1,CL1 cell line expresses both CK14 and E-cadherin
uniformly in all of the cells (Figure 3B). Together, the results in
Figure 3, A and B, indicate that the cell lines derived from the
MMTV-D1K2 tumors exhibit a mixed luminal/myoepithelial pro-
tein expression pattern at the single-cell level.
A number of human mammary carcinoma cell lines have been
analyzed in microarray experiments and classified into luminal or
basal-like subgroups [24]. Interestingly, analysis of some of these
mammary carcinoma cell lines by immunoblot suggests that human
Figure 1.MMTV-D1K2 hypercellular lesions invade into the mammary stroma. (A) Representative mammary MMTV-D1K2 tumor section
stained with hematoxylin and eosin (H&E) at low- and high-magnification display areas of poorly differentiated cells invading into the
surrounding mammary fat pad. (B) Tumors derived from MMTV-neu tumor cells stained with Masson’s Trichrome exhibit distinct tumor
cell compartmentalization from the surrounding stroma. (C) Phase-contrast micrographs of nontransformed mouse mammary NMuMG
cells, MMTV-D1K2 tumor–derived cell lines D1K2-T2 and D1K2-T4, and the BT549 human basal-like breast cancer cell line.
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Figure 2. Cell lines derived from MMTV-D1K2 tumors exhibit protein expression profiles consistent with basal-like breast cancer. (A)
Immunoblot analysis of cells derived from MMTV-D1K2 tumors, an MMTV-neu tumor (neuT), and the BT549 basal-like human mammary
carcinoma cell line, using antibodies specific for N-cadherin (N-Cad.), E-cadherin (E-Cad.), P-cadherin (P-Cad.), EGFR, vimentin, CK14, αSMA,
nestin, p120 catenin (p120ctn), β-catenin, zyxin, p53, p130, the cyclin D1–Cdk2 fusion protein [detected with a Cdk2 antibody (Cdk2(D1K2))],
Her2/neu (neu), and actin as a loading control. D1K2-T2,CL1 and D1K2-T2,CL6 are clonal cell lines derived from the D1K2-T2 cancer cell line.
(B) Immunoblot analysis of primary MMTV-neu and MMTV-D1K2 tumors (arbitrarily labeled A–G) using antibodies specific for Flag [detecting
the cyclin D1–Cdk2 fusion protein (Flag(D1K2))], Her2/neu, E-cadherin (E-Cad.), αSMA, vimentin, Rb, Rb phosphorylated on residues 249/
252 (P-Rb[249/252]), Rb phosphorylated on residues 807/811 (P-Rb[807/811]), and actin as a loading control. (C) Immunoblot analysis of the
indicated cell lines with the indicated antibodies. “–D1K2” represents expression of the cyclin D1–Cdk2 fusion protein detected with either
cyclin D1 or Cdk2 antibodies. “End. Cyclin D1” and “End. Cdk2” represent levels of endogenous cyclin D1 and Cdk2.
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breast carcinomas may also frequently exhibit a luminal/myoepithelial
mixed-lineage phenotype (Figure 3C). The T47D, MCF7, and MDA-
MB-361 cell lines, classified as luminal by microarray analysis, express
the myoepithelial marker P-cadherin. Likewise, the MDA-MB-468
and BT549 cell lines, classified as basal by microarray analysis, express
the luminal marker E-cadherin (Figure 3C ). In contrast, the non-
transformed mouse mammary gland NMuMG cell line does not ex-
press P-cadherin, and the nontransformed human basal-like cell lines
Figure 3. MMTV-D1K2 tumor cell lines exhibit mixed luminal/myoepithelial lineage. (A) Immunoblot analysis of clonal MMTV-D1K2 can-
cer cell lines using the antibodies listed in Figure 2, and a CK19 antibody. Clonal lines are designated by the name of the original cell
line followed by the clone number. (B) Immunofluorescence micrographs showing nuclear DAPI staining (blue) in the no primary anti-
body control (No 1°), CK14 staining (CK14, orange), E-cadherin staining (E-Cad., green), and a merged image showing coexpression of
E-cadherin and CK14 at the single-cell level (CK14 + E-Cad. + DAPI). (C) Immunoblot analysis of human mammary carcinoma cell lines
(T47D, MCF7, MDA-MB-361, MDA-MB-468, BT549, MDA-MB-231, MDA-MB-435s, and MDA-MB-436) and nontumorigenic mammary
epithelial cell lines (NMuMG, MCF10A, and HBL100) was performed using the indicated antibodies.
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MCF10A and HBL100 do not express E-cadherin. p53 overexpression
in the T47D, MDA-MB-468, BT549, MDA-MB-231, and MDA-
MB-435s carcinoma cell lines is expected because these cells harbor
mutant p53 alleles [25–28].
MMTV-D1K2 Tumor–Derived Cell Lines Form Invasive
Tumors In Vivo
Basal-like tumors are often invasive; therefore, we examined
whether the MMTV-D1K2 tumor–derived cell lines would form in-
vasive tumors in vivo. The polyclonal D1K2-T1, D1K2-T2, D1K2-
T4, and D1K2-T5 cell lines were injected into the mammary glands
of three wild type female FvB mice. All of the mice formed tumors
from 2 to 6 weeks after injection. The tumors exhibited invasion into
the surrounding mammary fat pad and muscle (Figure 4A). Invasion
of individual cancer cells between adipocytes and muscle fibers was
observed at the tumor/stroma interface. The infiltrative tumors ex-
hibited inclusions of adipocytes. The disorganized and poorly differ-
entiated appearance of the tumors is similar to that of the cells in
hypercellular lesions in the MMTV-D1K2 transgenic mammary
glands that exhibit invasion into the fat pad (Figure 1A). The blue
Trichrome staining at the invading edge of the tumors (Figure 4A;
D1K2-T1 and D1K2-T2) coincides with cells of fibroblastic mor-
phology and is indicative of desmoplasia and fibroblast infiltration
into the tumors. The MMTV-D1K2 cell line–derived tumors were
negative for ER and progesterone receptor expression and Her2 over-
expression by immunohistochemistry (data not shown), consistent
with the expression pattern of the cell lines in vitro (Figure 2, A
and C ). The finding that some of the D1K2 cell lines express high
levels of E-cadherin in cell culture (Figures 2B and 3A) seems in-
consistent with the poor ability of the cells to form distinct colonies
in vitro (Figure 2A) and with the invasiveness of the cell lines ob-
served in vivo (Figure 4A).
Immunohistochemistry experiments examining the localization of
E-cadherin within the tumors demonstrated that the noninvasive
tumors derived from neuT cells exhibit strong E-cadherin staining
at cell-cell junctions (Figure 4B) and lack expression of αSMA and
CK14 (not shown). In contrast, tumors derived from the D1K2-
T1, D1K2-T4, and D1K2-T5 cell lines exhibit weak, diffuse cyto-
plasmic E-cadherin staining, suggesting that E-cadherin localization
to the cytoplasm contributes to the invasiveness of these cell lines.
The D1K2-T1, D1K2-T2, and D1K2-T4 cell line–derived tumors
also express variable levels of CK14 (Figure 4C ). The positive stain-
ing of the tumors for both E-cadherin and CK14 suggests that
the tumors, like the initiating cell lines, exhibit a mixed luminal/
myoepithelial phenotype.
We next examined whether populations of cancer cells with
a mixed-lineage phenotype were present in the primary MMTV-
D1K2 tumors. The primary tumor from which the D1K2-T1 cell
line was derived has a biphasic morphology characteristic of adeno-
myoepithelial-type carcinoma, with both glandular structures and
clusters of less differentiated spindle-shaped cells (Figure 4D). Immu-
nohistochemical staining of serial tumor sections showed that these
spindle-shaped cells stain positively for E-cadherin diffusely localized
to the cytoplasm and show positive staining for αSMA. In contrast,
the surrounding glandular structures are composed of cells that ex-
press E-cadherin at their cell-cell junctions and lack αSMA expres-
sion. This observation suggests that the primary MMTV-D1K2
tumors contain both luminal/myoepithelial mixed-lineage cell popu-
lations and cells that exhibit a luminal-like staining pattern. Thus, it
seems likely that the basal-like cancer cell lines isolated from the
MMTV-D1K2 tumors represent the spindle-shaped subpopulation
of cells present in the primary tumors.
MMTV-D1K2 Tumors Resemble Human Basal-like
Breast Cancers
MMTV-D1K2 cancer cells resemble human basal-like breast can-
cer cell lines in terms of their morphology, protein expression pat-
terns, and invasiveness in vivo. Therefore, we examined how the
morphology of the MMTV-D1K2 tumors compares with that of
human basal-like (triple negative) breast tumors. The representative
triple-negative breast tumor shown is from a 58-year-old white
female with grade III invasive ductal carcinoma. This tumor was veri-
fied to lack ER and Her2 overexpression in two separate immuno-
histochemical analyses (data not shown). The tumor contains a
necrotic core and an expanding boundary that invades into the sur-
rounding mammary fat pad and contains inclusions of adipocytes
(Figure 5A).
Immunohistochemical staining shows that the tumor cells express
αSMA, E-cadherin, and CK14. Red Van Gieson’s staining indicates
that the tumor contains extensive collagen deposits (fibrosis) inter-
spersed between clusters of cancer cells. This fibrosis colocalizes with
tumor-associated fibroblasts. In many areas of the tumor, the tumor-
associated fibroblasts make up a larger fraction of the tumor volume
than the cancer cells. We also examined whether the MDA-MB-231
and MDA-MB-436 cell lines, which exhibit basal-like expression
profiles [24], form tumors that display features similar to human
basal-like breast cancers and similar to tumors formed from MMTV-
D1K2 cancer cell lines. Ten million cells of each line were injected
orthotopically into three adult female athymic nude mice. The ani-
mals developed tumors from 3 to 6 weeks after injection. Tumors
were excised when they reached 2 to 6 mm in diameter so that in-
vasion into the surrounding stroma could be visualized. Figure 5B
shows that MDA-MB-231 and MDA-MB-436 tumors grown as
xenografts in athymic nude mice form invasive tumors that contain
inclusions of adipocytes, exhibit fibroblast accumulation and fibrosis
at the tumor/stroma boundary, and develop a fibrotic necrotic core
when tumors grow larger than approximately 3 mm in diameter. The
invasive growth pattern of the MDA-MB-231 cells in vivo is similar
to that observed with the MMTV-D1K2 tumor–derived cell lines.
MMTV-D1K2 Tumor–Derived Cell Lines Exhibit Extensive
Stress Fiber Formation and Cytoplasmic E-cadherin, p120ctn,
and β-Catenin Localization
Primary myoepithelial cells exhibit constitutive stress fibers in cul-
ture [22]. Zyxin is a component of focal adhesions and associates
with actin stress fibers [29]. Immunoblot experiments (Figure 2B)
indicate that the D1K2 tumor cell lines express higher levels of zyxin
and nestin than the neuT cell line. Therefore, we examined zyxin
localization and colocalization with actin in immunofluorescence
microscopy studies (Figure 6A). The neuT cells grow as colonies
and exhibit cortical actin staining but no detectable stress fibers.
Zyxin is present primarily at the outer border of the neuT colonies.
In contrast, the D1K2 cancer cell lines exhibit constitutive stress fiber
formation. Zyxin colocalizes with the ends of actin stress fibers and
is present around the periphery of each of the cells that is not part of
a colony.
It is unclear from the studies in Figures 1–4 whether the cyto-
plasmic E-cadherin localization observed in the tumors formed from
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Figure 4. Tumors formed from MMTV-D1K2 cancer cell lines exhibit stromal invasion and E-cadherin mislocalization/down-regulation
on orthotopic implantation. (A) Masson’s Trichome staining of histologic sections from tumors derived from D1K2-T1 cells invading into
the mammary fat pad (first panel), muscle (second panel), and a tumor derived from D1K2-T2 cells invading into the mammary fat pad
(third panel). Hematoxylin and eosin–stained section of a tumor derived from D1K2-T5 cells invading into the mammary fat pad (fourth
panel). (B) Immunohistochemical E-cadherin detection (brown staining) in histologic sections of tumors generated from the indicated
polyclonal cell lines. E-cadherin is localized to sites of cell-cell contact in neuT tumors (inset). In contrast, tumors formed from the D1K2-
T1, D1K2-T2, and D1K2-T4 cell lines exhibit weak, mosaic E-cadherin expression. E-cadherin is localized diffusely throughout the cyto-
plasm (e.g., D1K2-T2; inset) in cells that express it. (C) Cytokeratin 14 (CK14) immunohistochemical analysis of tumors generated from
the indicated polyclonal cell lines (red staining). (D) Hematoxylin and eosin histochemical staining of an MMTV-D1K2 primary tumor (left
panels) showing poorly differentiated spindle-shaped cell populations with abundant cytoplasm surrounded by more densely packed
cells. Immunohistochemical staining (brown) of serial sections of the same tumor for E-cadherin (E-Cad.; center panel) and αSMA (SMA;
right panel). Sections were counterstained with hematoxylin. Note the diffuse cytoplasmic E-cadherin staining (inset) and positive stain-
ing for αSMA in the compartments containing the spindle-shaped cells.
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the MMTV-D1K2 cancer cell lines results from environmental in-
fluences in the tumor milieu or is caused by intrinsic properties of
the cancer cells themselves. Immunofluorescence microscopy studies
indicate that the noninvasive neuT cancer cells form colonies in cul-
ture and that E-cadherin and the E-cadherin–associated protein
p120ctn localize to cell-cell contacts in these colonies (Figure 6B).
In contrast, in several of the D1K2 tumor cell lines, E-cadherin
and p120ctn are largely localized to the cytoplasm. This is not specific
to the D1K2 cancer cell lines because the BT549, MDA-MB-435s
(Figure 6B), MDA-MB-231, and MDA-MB-436 (data not shown)
Figure 5. Basal-like breast cancers exhibit an invasive, mixed-lineage phenotype and tumor-associated fibrosis. (A) The top panel shows
an H&E–stained histologic section (center) of a triple-negative human breast adenocarcinoma. The top right and top left panels show
invasion of the tumor into the surrounding fat pad and inclusions of adipocytes in the tumor (inset). The second row of panels demon-
strates immunohistochemical staining for the myoepithelial markers αSMA and CK14 and the luminal marker E-cadherin (E-cad.). The
bottom panel shows Van Gieson’s staining of the tumor. The cancer cells stain brown. The intense red staining between the cancer cells
shows extensive collagen deposition, indicative of tumor-associated fibrosis. (B) MDA-MB-231 and MDA-MB-436 cell lines were grown
as orthotopic xenograft tumors in athymic nude mice. Upper panels show H&E–stained histologic sections and lower panels show serial
sections stained with Masson’s Trichrome. Arrows in the MDA-MB-231 panels point out fibroblasts/fibrosis at the advancing tumor front
and the infiltration of cancer cells between stromal adipocytes. Arrows in the leftmost MDA-MB-436 panel point out numerous blood
vessels at the advancing tumor boundary that colocalize with the extensive fibrosis at tumor/stroma interface. Arrows in the rightmost
MDA-MB-436 panel show the necrotic, fibrotic center of a 4-mm tumor.
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human basal-like breast cancer cell lines also exhibit punctate cyto-
plasmic E-cadherin localization and diffuse cytoplasmic p120ctn lo-
calization. E-cadherin also functions to sequester β-catenin by
localizing it to adherens junctions and preventing it from translocat-
ing to the nucleus and functioning as a transcriptional coactivator.
E-cadherin localization to the cytoplasm (or loss of E-cadherin ex-
pression as observed in the D1K2-T5,CL1 cell line) correlates with
decreased junctional β-catenin staining in the D1K2 and BT549
cell lines (Figure 6C ). These observations are significant because
E-cadherin is thought to function as a tumor suppressor by mediat-
ing cell-cell adhesion and by restraining the proinvasive oncogenic
effects of β-catenin [30–32] and p120ctn [14,33,34].
Discussion
MMTV-D1K2 Tumors
Cyclin D1 is overexpressed in approximately 40% to 50% of
human breast cancers [35,36], but cyclin D1 overexpression typically
occurs in luminal tumors rather than in basal-like breast cancers [11].
Figure 6. MMTV-D1K2 tumor–derived cell lines exhibit extensive stress fiber formation and E-cadherin, p120ctn, and β-catenin localiza-
tion to the cytoplasm. (A) Immunofluorescence micrographs of the indicated cell lines stained for zyxin (green), actin (orange), and DNA
(DAPI, blue). (B) Immunofluorescent staining (yellow) for E-cadherin (upper panels) and p120ctn (p120, lower panels). The cells were
counterstained for DNA (DAPI, blue). E-cadherin and p120ctn are localized to cell-cell junctions in the neuT cells but are largely localized
to the cytoplasm in the D1K2-T2,CL1, D1K2-T4,CL1, D1K2-T5,CL1, BT549, and MDA-MB-435s cell lines. (C) Immunofluorescent staining
for E-cadherin (orange) and β-catenin (green) in the indicated cell lines showing that in the neuT cells, E-cadherin and β-catenin localize
to cell-cell contacts; whereas in the D1K2-T2,CL1, D1K2-T5,CL1, and BT549 cell lines, E-cadherin and β-catenin do not colocalize. The
cells were counterstained for DNA (DAPI, blue).
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Cyclin E overexpression has been noted in basal-like breast cancers
[37]. Cyclin E overexpression in breast cancers correlates with ER
negativity and poor prognosis, whereas cyclin D1 overexpression cor-
relates with ER expression and a favorable outcome [38]. Cyclin E
potently activates Cdk2, and the cyclin D1–Cdk2 fusion protein
functions as a constitutively active form of Cdk2 [12,13].
Whether any type of constitutive Cdk2 activation is sufficient to
induce basal breast cancer formation requires further study. The ani-
mal models of basal-like breast cancer constructed to date involve ge-
netic inactivation of BRCA1 and p53 [7,39]. It is unknown whether
the cyclin D1–Cdk2 fusion protein induces the formation of basal-
like cancer cells through a mechanism distinct from BRCA1 and p53
deletion or whether expression of the cyclin D1–Cdk2 fusion protein
is functionally equivalent to BRCA1 and p53 deletion. Interestingly,
Cdk2 has recently been shown to inhibit the ubiquitin ligase activ-
ity of the BARD1/BRCA1 complex [40], and the BARD1/BRCA1
ubiquitin ligase complex seems to mediate the tumor-suppressive
functions of the BRCA1 gene [41]. p53 function is frequently lost
in breast cancers, and p53 inactivation is thought to contribute to
cell invasiveness [42]. p53 also suppresses tumorigenesis in part by
inducing expression of the Cdk inhibitor p21. p21-mediated inhibi-
tion of proliferation plays a critical role in suppressing tumorigenesis
in some contexts [43]. We have shown previously that D1K2 can
function to sequester p21 and p27 [12,13]; therefore, D1K2 may
partially override p53 function, with respect to p21.
“Mixed-Lineage” Characteristics of MMTV-D1K2 Tumor
Cell Lines
Previously, studies of transgenic mouse breast cancer models (re-
viewed in Sutherland and Musgrove [44]) showed that expression of
cyclin D1 in the mammary gland under the control of the MMTV
promoter resulted in adenocarcinomas in 75% of the mice, although
some squamous differentiation was observed [45]. MMTV–cyclin
D2 transgenic mice also develop adenocarcinomas albeit at a lower
frequency (19%) [46]. In contrast, MMTV–cyclin D3 mice form
primarily squamous cell carcinomas [47]. These studies indicate
that the type of cell cycle deregulation that drives tumor formation
can influence the differentiation status of the resulting tumors. The
MMTV–cyclin D1–Cdk2 transgenic mouse tumors described here
are morphologically heterogeneous, including metaplastic, adeno-
squamous, and adenomyoepithelial-type carcinomas [13]. The
spindle cell myoepithelial-like component of these tumors stains pos-
itively for E-cadherin and αSMA and exhibits E-cadherin mis-
localization to the cytoplasm. Cell lines isolated from these tumors
exhibit several similarities with human basal-like breast cancers in-
cluding the following: 1) the expression of myoepithelial markers
such as αSMA, nestin, CK14, and EGFR; 2) lack of Her2 over-
expression and lack of ERα expression; 3) the expression of subsets
of luminal markers including E-cadherin, CK18 (not shown), and
CK19, consistent with the luminal/myoepithelial “mixed-lineage”
nature of human basal-like breast cancers [15,16,48]; 4) the cells
exhibit myoepithelial-like morphology and cytoskeletal features
in vitro; 5) the cell lines form invasive tumors with spindle mor-
phology in wild type mouse mammary fat pads in vivo; and 6) the
cells seem to have undergone EMT that has recently been shown to
occur in the basal-like subtype of breast tumors [19]. MMTV–cyclin
D1–Cdk2 transgene expression in a mammary stem–like cell might
explain the observed heterogeneity in tumor morphology. Alterna-
tively, cyclin D1–Cdk2 expression may inhibit lineage specification
or block differentiation. Both of these hypotheses are consistent with
the observation that the markers CK14 and nestin expressed in the
MMTV–cyclin D1–Cdk2 tumor cell lines are associated with rela-
tively undifferentiated cell populations [17,49–53].
MMTV-D1K2 Invasiveness
Several non–mutually exclusive mechanisms could contribute to
the invasiveness of MMTV-D1K2 tumors including E-cadherin mis-
localization/down-regulation and expression of proteins previously
correlated with invasiveness such as nestin [54] and zyxin [55].
The role of Cdk2 activation in these processes is unclear. Chronic
treatment with the Cdk2 inhibitor roscovitine did not revert the
MMTV-D1K2 cell lines to a luminal-like morphology or increase
the formation of adherens junctions in culture (data not shown). It
is possible that Cdk2 activation directly influences cell invasiveness,
perhaps by functionally inactivating Rb. Recently, it has been shown
that knock-down of Rb expression by short-interfering RNA de-
creases E-cadherin expression and induces EMT [56]. However, it
is also possible that Cdk2 activation induces irreversible changes to
the cells that result in increased invasiveness. The mixed-lineage na-
ture of the MMTV-D1K2 cells may result from an alteration in the
normal differentiation program that causes increased invasiveness.
The observation that invasive human basal-like breast cancer cell
lines exhibit the same E-cadherin down-regulation/mislocalization
and mixed-lineage expression pattern is consistent with this hypothesis.
We have shown previously that MMTV-D1K2 cell lines exhibit
aneuploidy [13]. Cdk2 activation may induce genetic instability that
results in subpopulations of tumor cells with increased invasive prop-
erties. The observation that the D1K2-T4 cells do not express D1K2,
but exhibit E-cadherin mislocalization, a mixed-lineage phenotype,
and invasiveness in vivo, raises the possibility that D1K2 initiates
the formation of a subpopulation of invasive cells but is not required
for its maintenance. Intriguingly, the D1K2-T4 cells exhibit alterations
that might mimic D1K2 function and mediate invasiveness in its ab-
sence, including p53 mutation [42] and decreased Rb expression [56].
Another potential explanation for the E-cadherin down-regulation
and cytoplasmic localization is the production of TGFβ by the
MMTV-D1K2 cancer cells. We have previously shown that the
MMTV-D1K2 cells secrete TGFβ [13]. Transforming growth factor
β is capable of inducing EMT associated with E-cadherin down-
regulation/cytoplasmic localization [57]. Transforming growth factor
β signaling has been associated with basal-like breast cancers [58–60],
and EMT has been specifically associated with basal-like tumors
[19]. Chronic treatment with a TGFβ type I receptor kinase in-
hibitor did not convert the MMTV-D1K2 cell lines to a luminal
morphology in culture (data not shown). However, autocrine TGFβ
might function to induce an aberrant luminal/myoepithelial mixed-
lineage differentiation status that cannot be reversed by blocking
TGFβ signaling. The previously observed tumor-associated fibrosis
(desmoplasia) in the MMTV-D1K2 tumors [13] is recapitulated in
the tumors generated from the MMTV-D1K2 tumor–derived cell
lines (Figure 4A). This suggests that the desmoplasia is caused by the
cancer cells themselves and rules out possible effects caused by trans-
gene expression in the stroma. Desmoplasia initiated by the MMTV-
D1K2 cancer cells could result from TGFβ production because TGFβ
is well known to induce fibrosis and desmoplasia [61,62].
In summary, the evidence presented here suggests that constitu-
tively active Cdk2 in the form of a cyclin D1–Cdk2 fusion protein
induces tumors that contain an invasive component that exhibits
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multiple features in common with human basal-like tumors and
tumor-derived cell lines. Current efforts are focused on understand-
ing the respective roles of Cdk2 hyperactivation, genetic instability,
and TGFβ production in the formation of the invasive basal-like can-
cer cells in the MMTV-D1K2 tumors. It is hoped that these studies
will yield insights into the mechanisms responsible for the invasive-
ness of human breast tumors.
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